Noven is a fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise

Product Development

Product Development

Pipeline Opportunities

Noven’s Product Development capabilities and expertise extend from product formulation to product approval and beyond. Our capabilities include in-house product formulation, development, clinical testing, and regulatory and medical affairs. In its history, Noven has received FDA approval for eight products, and currently has applications for two developmental products pending.

Noven is also working collaboratively with its parent company, Hisamitsu, to develop new prescription transdermal systems, and potentially new transdermal technologies that could extend the number of compounds that can be delivered through the skin, bringing the benefits of patch therapy to patients around the world.

The following table summarizes the status of products marketed, approved, and/or under development by Noven. Developmental products are identified in yellow.


Product

Indication
Regulatory Status Marketing
Rights
Noven Therapeutics Central Nervous System
Daytrana® (methylphenidate transdermal system) ADHD in children 6-17 years old Marketed in U.S. Noven
ATS ADHD Phase 2 Noven
Noven Therapeutics Women's Health
Minivelle®
(estradiol transdermal system)
Moderate to severe vasomotor symptoms and prevention of post-menopausal osteoporosis Marketed in U.S. Noven
CombiPatch®
(estradiol / NETA transdermal system)
Moderate to severe vasomotor symptoms; moderate to severe vulvar and vaginal atrophy; treatment of hypoestrogenism Marketed in U.S. Noven
Pain Management
Lidocaine Topical Patch (generic) Pain associated with post herpetic neuralgia Pending
Undisclosed
Other Areas
Rivastigimine Transdermal System (generic) Mild to moderate dementia of the Alzheimer's type; Mild to moderate dementia associated with Parkinson's disease Pending
Noven
Parent Company Collaboration
Multiple Undisclosed Projects Various Pre-clinical and clinical development Hisamitsu/Noven